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1. Introduction 
There are many female causes for infertility but the incidence of infertility increases with 
advancing age. Colombat de L'Isere in a chapter on ‘Change of Life' in his “Treatise on the 
diseases and special hygiene of females” (1845) stated: Compelled to yield to the power of 
time, women now cease to exist for the species, and hence forward live only for themselves” 
(Colombat de L’Isere M., 1945). Fortunately, this pessimistic outlook on life after menopause 
has become outdated. Aiming to standardize terminology The World Health Organization 
(WHO) assembled in 1996 and the Council of Affiliated Menopause Societies (CAMS) in 
1999 (WHO Scientific Group: Research on Menopause in the 1990s, Utian WH, 1999).  
Commonly accepted terms, including pre-menopause, peri-menopause, menopausal 
transition, and climacteric, were thought to be too vague to be useful. In July of 2001, the 
Stages of Reproductive Aging Workshop (STRAW) was held to address the absence of a 
relevant staging system for female reproductive aging, and to discuss the confusing current 
nomenclature for the pre-menopause (Soules MR, et al., 2001).  
The average age of menopause is 51 and less than 1% of women experience it before the age 
of 40. Some women undergo premature menopause at a very early age affecting their ability 
to have children. As more and more women delay child bearing, this life altering condition 
has become more prevalent. Population aging must be added to population growth as very 
important social problems.  Women in our society get married and have children later in 
life. Therefore, evaluation of ovarian reserve is critical to understanding a patient’s 
reproductive potential. 
Ovulatory disorders are a common cause of infertility. Ovulation is controlled by complex 
interactions between numerous endocrine hormones including FSH, LH, estradiol, 
progesterone and others. Menopause is the cessation of the primary functions of the human 
ovaries, with associated changes in pituitary gonadotropin secretion occurring secondary to 
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the decline in ovarian sex steroid and protein production. However, increasing evidence 
suggests that aging is associated with dynamic changes in the hypothalamic and pituitary 
components of the reproductive axis that are independent of changes in gonadal hormone 
secretion (Hall JE, et al., 2000). Imbalances in these hormones, or alterations in the “feedback 
mechanism”, can prevent ovulation, or cause it to be irregular.   
2. Epidemiology of menopause  
Most estimates of age at natural menopause are based on samples of Caucasian women in 
Western societies. In one large, comprehensive, prospective cohort study of mid-aged, 
Caucasian U.S. women (the Massachusetts Women's Health Study [MWHS]) the age at 
natural menopause occurred at 51.3 years, (Gold EB, et al., 2001) confirming prior reports. 
The Study of Women's Health Across the Nation (SWAN), a multicenter, multiethnic, 
community-based cohort study of women and the menopausal transition, reported the 
overall median age at natural menopause to be 51.4 years, after adjustment for other factors 
(Gold EB,  et al., 2001).  Studies performed outside the United States suggest that Africans, 
African Americans, (Bromberger JT, et al., 1997) and Hispanics of Mexican descent 
experience menopause at an earlier age than Caucasian women, as opposed to Japanese 
(Tamada T & Iwasake H., 1995) and Malaysian (Ismael NN., 1994) women, who report a 
similar median age of menopause to women of European descent. 
Lower educational attainment and unemployment have been independently associated with 
earlier age at menopause (Gold EB, et al., 2001; Cramer DW, 1994 et al) and may be markers 
for elevated bio-psychosocial stress. Women who are separated, divorced, or widowed have 
been shown to have an earlier menopause than women who are married (Gold EB, et al., 
2001). Age at natural menopause for parous women has been reported to occur significantly 
later than for nulliparous women. (Gold EB, et al., 2001; Anasti JN., 1998; Tibilette MG, et al., 
1999;  Weel AE, , et al., 1999).  Gold et al. and Cramer et al. observed a trend of increasing 
age at menopause with increasing number of life births, and that prior use of oral 
contraceptives was associated with earlier age at natural menopause however, a slight 
prolongation of the reproductive life-span has been associated with oral contraceptive use  
(Cramer DW, et al., 1994).  
The proposed mechanism by which parity and use of oral contraceptives may result in later 
age at natural menopause involves reducing ovulatory cycles earlier in life and thus 
preserving oocytes longer, resulting in later menopause (Gold EB, et al., 2001). Some studies 
show that women with a lower body mass index (BMI) experience an earlier menopause; 
other studies have not confirmed this finding (Zapantis G & Santoro N., 2002). 
Environmental toxicants may play a role in early menopause. A large body of literature 
shows that current smokers tend to experience menopause at an earlier age (1 to 2 years) 
than non-smokers (Reynaud K,, et al, 2001, Hreinsson JG, et al., 2002,  Loffler KA, et al., 
2003,  Burger HG, et al., 2002) and may have a shorter menopausal transition (Gold EB, 2001, 
et al).  
It has been shown that polycyclic hydrocarbons in cigarette smoke are toxic to ovarian 
follicles and may lead to their loss and thus an earlier menopause in smokers. Harlow et al. 
observed that women with a history of medically treated depression had a 20% increased 
rate of entering peri-menopause sooner than women with no depression history, after 
adjustment for age, parity, age at menarche, education, cigarette smoking, and BMI. 
Epidemiology gives answers about populations, whereas clinical medicine deals with 
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patient samples and individuals. For example, in population-based studies, (Gold EB, et al., 
2001) no global increased prevalence of depression has been associated with the menopause 
transition, whereas in clinical samples, depression around menopause has reportedly 
increased. Furthermore, symptoms vary among women, and the distinction between 
populations versus individuals must be made when one is evaluating epidemiologic factors 
related to menopause. 
3. Menopause pathogenesis  
The basis of reproductive senescence in women is oocyte/follicle depletion in the ovary. 
Developmentally, a woman attains her peak oocyte complement at 20 weeks’ gestational 
age. Between 20 and 40 weeks’ gestation, two thirds of a woman's oocyte complement is 
lost, and total oocyte counts drop from a mean of about 6 to 8 million to 1 to 2 million 
(Zapantis G & Santoro N., 2002). 
The most massive wave of atresia (rate of follicle loss) that a woman ever experiences 
happens before she is born. At the onset of puberty, germ cell mass has been reduced to 
300,000 to 500,000 units. Subsequent reproductive aging consists of a steady loss of oocytes 
through atresia or ovulation and does not necessarily occur at a constant rate. Atresia is an 
apoptotic process. During the 35 to 40 years of reproductive life, 400 to 500 oocytes will be 
selected for ovulation. By menopause, only a few hundred follicles remain (Speroff L, et al., 
1999). 
The relatively wide age range (42 to 58 years) for menopause in normal women seems to 
indicate that women may be endowed with a highly variable number of oocytes, or that the 
rate of oocyte loss varies greatly (Soules MR, et al., 2001). Concurrent with the loss of 
ovarian follicles as a woman transitions to menopause are hormonal changes in the 
hypothalamic-pituitary-ovarian axis. Follicle-stimulating hormone (FSH) is an established 
indirect marker of follicular activity; as follicle numbers decline, FSH levels increase (Burger 
HG, et al., 2002). An elevated level is often the first clinically measurable sign of 
reproductive aging. Large cross-sectional studies have reported a progressive, quantitative 
rise in FSH with age (Ahmed-Ebbiary NA, et al., 1994). In the late reproductive years, initial 
elevations in FSH are most prominent in the early follicular phase of the menstrual cycle but 
are intermittent and do not occur in every cycle (Klein NA, Soules MR., 1998). This increase 
is first detectable some years before any clinical indications of approaching menopause are 
evident (Burger HG, et al., 2002). 
The rise in FSH appears to be the result of a decline in inhibin -B, a dimeric protein that reflects 
the fall in ovarian follicle numbers.  Is a small pleomorphic peptide made within the ovarian 
granulosa and luteinized granulosa cells, which, although assay specificity and sensitivity in 
ovarian physiology (Burger HG 1993). Inhibin may be an intraovarian regulator although other 
peptides such as activin and follistatin are more likely paracrine factors (Findlay JK, et al., 
1990) but one of its more important functions appears to be feedback suppression of FSH 
production (Seifer DB, et al., 1996). In reproductive life, inhibin serves to selectively inhibit 
FSH by binding to receptors on the anterior pituitary (Robertson DM & Burger HG., 2002). 
Estradiol is stable or even elevated during the earlier menopause transition; closer to the final 
menstrual period, a decline is clearly observed (Longscope C, et al., 1986). 
Findings from the Melbourne Women's Midlife Health Project, a cohort of women followed 
through the menopause transition, confirm that a decline in inhibin B precedes the increase 
in FSH and the decline in estradiol that occur later in the transition (Burger HG, et al., 2007). 
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The remaining follicles are less likely to function normally, which may lead to erratic 
follicular development and dysregulation of folliculogenesis (Whiteman MK, et al., 2003, 
Schwingl PJ, et al., 1994). Although FSH and estradiol vary near menopause, steroidogenic 
enzymes appear to be completely absent in the postmenopausal ovary after all functional 
follicles are lost (Couzinet B, et al., 2001). Between the ages of 20 and 40 years, 
concentrations of total testosterone have been reported to fall by about 50% (Zumoff B, et al., 
1995). This age-related decline does not change further during the transition years (Burger 
HG, et al., 2000). Similarly, dehydroepiandosterone (DHEA) and its sulphate, DHEAS, 
decline with age (Rossmanith W et al., 1991., Santoro N, et al., 1998). Because circulating sex 
hormone–binding globulin (SHBG) decreases across the menopausal transition, free 
androgen levels actually rise, as indicated by a small increase in free androgen index (T ÷ 
SHBG × 100) (Burger HG, et al., 2000). Androstenedione, which remains relatively stable 
during the transition, is converted to estrone in extra-glandular tissue. This accounts for 
almost all the estrogen in circulation after menopause.  
When ovulation stops, concurrent with a woman's FMP, serum progesterone levels are 
invariably low (Rannevik G, et al., 1995). Luteinizing hormone (LH) eventually increases, 
although at a slower rate than FSH. Despite the epidemiologic trend toward elevated FSH 
and decreased estradiol with progression through the transition, measurement of FSH, 
inhibin, and estradiol provides at best an unreliable guide to the menopausal status of an 
individual woman (El-Hage G, et al., 2007; Braunstein GD, et al., 2005). A more rational 
approach to diagnosing menopause would include an assessment of the longitudinal 
symptoms of a woman who presents with peri-menopausal complaints (Lobo RA., 1999). 
Hormone profiles correlate well with symptoms and cycle features (Burger HD, et al., 1995). 
Thus, if a woman is >45 years old and has had a recent disruption in her menstrual pattern 
and symptoms suggestive of transient hypo-estrogenemia, it is likely that she has entered 
her menopausal transition (Santoro N., 2002). That being said, the clinician should take care 
to rule out other pathologies that can be masked by common complaints associated with the 
menopausal transition. At minimum, a screening TSH level should be performed, as 
menstrual irregularity may be the only manifestation of thyroid dysfunction. 
4. Regulation of gonadotropins and control of ovarian steroid production 
Pituitary gonadotropes synthesize and secrete both LH and FSH. They account for 7% to 
15% of anterior pituitary cells. Gonadotropin subunit gene expression is regulated by the 
frequency of GnRH signal input to pituitary gonadotropes (Haisenleder DJ, et al., 1991). 
During the menstrual cycle, LH pulse frequency is approximately every 90 minutes in the 
early follicular phase, 60 to 70 minutes during the late follicular phase, 100 minutes during 
the early luteal phase, and 200 minutes during the late luteal phase. This variation reflects 
changes in GnRH pulse frequency, which regulates relative FSH and LH secretion; this, in 
turn, determines follicle recruitment, development, and ovulation. More rapid GnRH pulse 
frequencies promote LH secretion, and slower frequencies promote FSH secretion. Although 
good evidence indicates that changes in GnRH pulse frequency determines differential LH 
and FSH secretion (Marshall JC, et al., 1993) it is apparent that ovarian steroids and peptide 
hormones have a major role. Women with hypothalamic stalk section regain their 
characteristic cycle length when administered an unchanging frequency of exogenous 
GnRH pulses every 90 minutes. 
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This indicates that intrinsic rates of follicle development and regression of the corpus 
luteum, along with their phasing of steroid and peptide hormone production, are major 
determinants of LH and FSH responses to GnRH. Gonadotropins control the growth and 
differentiation of the steroid hormone–secreting cells of the ovary, intrinsically linking form 
and function. A defined sequence of gonadotropin action propels the growth of follicles and 
the production of steroid hormones. Positive feedback on the pituitary by high 
concentrations of estrogens leads to the ovulatory surge of LH, which in turn triggers a 
dramatic differentiation event, resulting in structural reorganization of the pre-ovulatory 
follicle, release of the ovum, and striking changes in the steroidogenic capacity of the 
luteinizing cells. Follicular growth, which culminates in ovulation and corpus luteum 
formation, requires both FSH and LH. Steroidogenic competence of the ovarian follicle is not 
achieved in the absence of FSH, even if LH is present in abundance. FSH promotes 
proliferation of the granulosa cells and induces the expression of genes involved in estradiol 
biosynthesis (Haisenleder DJ, et al., 1991; Kaiser UB, et al., 1997). During the last phase of 
follicular maturation, when granulosa cells acquire LH receptors, LH is then able to sustain 
follicular estradiol synthesis. This LH substitution is thought to compensate for the 
diminished levels of FSH of the late follicular phase consequent to negative-feedback action 
of estradiol and inhibin. LH action on the granulosa thus rescues the dominant LH-
expressing follicle from the fate of atresia. LH stimulation is indispensable for normal 
ovarian hormone production not only before but also after ovulation. Suppression of LH 
release leads to a prompt decline in progesterone levels that precede changes in the 
abundance of mRNAs encoding steroidogenic enzymes or structural changes in the corpus 
luteum (King JA & Millar RP., 1982).  
This acute regulation of ovarian progesterone secretion is controlled by LH via the 
expression of steroidogenic acute regulatory protein (StAR) messenger RNA (mRNA) and 
protein, present in both theca-lutein and granulosa-lutein cells throughout the luteal phase 
are highly expressed in early and midluteal phase, whereas declining StAR mRNA and 
protein levels are characteristic of late luteal phase. Moreover, StAR protein levels in the 
corpus luteum are highly correlated with plasma progesterone levels; suppression of LH 
levels during the midluteal phase markedly decreases plasma progesterone levels and 
abundance of StAR mRNA transcripts in the corpus luteum (Millar RP, et al., 2004).  
4.1 Intra-ovarian control mechanisms  
The growth of follicles and the function of the corpus luteum, while under the primary 
direction of the pituitary, are highly influenced by intra-ovarian factors that modulate the 
action of gonadotropins. These intra-ovarian factors most likely account for gonadotropin-
independent follicular growth, observed differences in the rate and extent of development 
of ovarian follicles, arrest and initiation of meiosis, dominant follicle selection, and 
luteolysis. The list of potential paracrine factors that can influence steroid production by 
theca and granulosa cells is long and diverse. The previous theca cells lacked the aromatase 
enzyme that is necessary to produce estrogen (Schwanzel-Fukuda M, & Pfaff DW, 1984) so 
the production of estrogen in granulosa cells indicates presence of aromatase.  It includes 
various growth factors, cytokines, peptide hormones, and steroids such as epidermal 
growth factor, transforming growth factor ǃ (TGF-ǃ), platelet-derived growth factor, 
fibroblast growth factors, transforming growth factor ǂ (TGF-ǂ), activins, inhibins, Anti-
Müllerian hormone, insulin-like growth factors, estradiol, progesterone, and GnRH (Millar 
R: 2005; King JA, et al., 2002) 
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5. The peri-menopausal transition 
There is only one marker, menstrual irregularity that can be used to objectively define and 
establish what is called the peri-menopausal transition. This irregularity will be perceived 
by patients as skipped menstrual periods or longer durations (about 40 to 60 days) between 
periods (Harlow SD, et al., 2008) There is no universal pattern; each woman will perceive a 
change that is her own individual characteristic alteration. Literally means “about or around 
the menopause.” Generally speaking, the term “menopausal transition” is preferred over 
peri-menopause and climacteric.  
The menopause is that point in time when permanent cessation of menstruation occurs 
following the loss of ovarian activity. Menopause is derived from the Greek words men 
(month) and pausis (cessation). The years prior to menopause that encompass the change 
from normal ovulatory cycles to cessation of menses are known as the peri-menopausal 
transitional years, marked by irregularity of menstrual cycles. Climacteric, an older, more 
general, and less precise term, indicates the period of time when a woman passes from the 
reproductive stage of life through the peri-menopausal transition and the menopause to the 
postmenopausal years (Treloar AE, et al., 1967).  Menarche is followed by approximately 5–7 
years of relatively long cycles at first, and then there is increasing regularity as cycles 
shorten to reach the usual reproductive age pattern. In the 40s, cycles begin to lengthen 
again. The highest incidence of anovulatory cycles is under age 20 and over age 40 (Collett 
ME, et al., 1954). At age 25, over 40% of cycles are between 25 and 28 days in length; from 25 
to 35, over 60% are between 25 and 28 days. The perfect 28-day cycle is indeed the most 
common mode, but it totalled only 12.4% of Vollman’s study cycles. Overall, approximately 
15% of reproductive-age cycles are 28 days in length. Only 0.5% of women experience a 
cycle less than 21 days long, and only 0.9% a cycle greater than 35 days (Munster K, et al., 
1992).  
Most women have cycles that last from 24 to 35 days, but at least 20% of women experience 
irregular cycles (Belsey EM & Pinol APY, 1997). When women are in their 40s, anovulation 
becomes more prevalent, and prior to anovulation, menstrual cycle length increases, 
beginning 2 to 8 years before menopause (Treloar AE, et al., 1967). Cycles greater than 40 
days in length are prevalent in the year before menopause (Ferrell RJ, et al) The duration of 
the follicular phase is the major determinant of cycle length (Sherman BM, et al) This 
menstrual cycle change prior to menopause is marked by elevated follicle-stimulating 
hormone (FSH) levels and decreased levels of inhibin, but normal levels of luteinizing 
hormone (LH) and slightly elevated levels of estradiol (Buckler HM, et al., 1991;  
MacNaughton J, et al., 1992; Hee J, et al., 1993; Burger HG, et al., 2000,2008).  In the average 
woman, continuing follicular depletion and declining fertility begin at age 37–38, and 
menopause follows approximately 13 years later (average age 51).  However, in 
epidemiologic studies approximately 10% of women in the general population become 
menopausal by the age of 45, probably because they were born with a smaller than normal 
ovarian follicular pool that is functionally depleted at an earlier age. Menopause occurs 
when the number of remaining follicles falls below a critical threshold, about 1,000, 
regardless of age (Treloar AE, 1981).   
Recent longitudinal studies of women as they pass through the peri-menopausal transition 
reveal that estrogen levels do not begin a major decline until about a year before 
menopause. (Burger HG, et al., 2008; Lasley BL, et al., 2002).  Indeed, women experiencing 
the peri-menopausal transition actually have higher overall estrogen levels, a response that 
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is logically explained by an increased ovarian follicular reaction to the increase in FSH 
secretion during these years (Santoro N, et al). Variability in estrogen levels is characteristic 
of the peri-menopausal transition, with greater variability observed in menstrual cycles that 
display greater irregularity (Meyer PM, et al). As noted, most women experience a 2- to 8-
year period of time prior to menopause when anovulation becomes common (Treloar AE, et 
al., 1996). During this period of time ovarian follicles continue their rate of loss until 
eventually the supply of follicles is finally depleted (Gougeon A, et al., 1994). The age-
related changes in the endocrine characteristics of the menstrual cycle that result from 
progressive follicular depletion correlate with a measurable decrease in ovarian volume and 
in the number of antral follicles observed by trans-vaginal ultrasonography during the early 
follicular phase (Lass A, et al., 1997; Yong PY, et al., 2003; Frattarelli JL, et al., 2000; Dumesic 
DA, et al., 2001; Bancsi LF, et al., 2002; Kupesic S, et., 2003). The inverse and tight 
relationship between FSH and inhibin indicates that inhibin is a sensitive marker of ovarian 
follicular competence and, in turn, that FSH measurement is a clinical assessment of inhibin 
(MacNaughton J, et al., 1992; Hee J, et al., 1993).  The decrease in inhibin secretion by the 
ovarian follicles begins early (around age 35), but accelerates after 40 years of age. This is 
reflected in the decrease in fecundity that occurs with aging. The major decrease in estradiol 
levels began about 2 years before menopause (Sowers MR, , et al., 2008).  Declining levels of 
inhibin-B and Anti-Müllerian Hormone (AMH) reached a low to non-detectable point about 
5 years before menopause (Sowers MR, et al., 2008).  
Although the inhibin-B and AMH results are in general agreement with other reports, the 
exactness of the timing is limited by the fact that the blood samples were obtained from only 
50 women in the study. Nevertheless, the Michigan study confirms the validity of AMH as a 
marker for the ovarian reserve of follicles. Unlike inhibin-B, AMH is not a participant in the 
feedback relationship between the ovary and the pituitary gonadotropins, rather AMH, a 
product of granulosa cells, reflects the number of follicles present in the ovaries awaiting 
FSH stimulation (Visser JA, et al).  The variability in these measurements from individual to 
individual, however, precludes the practical use of these tests to predict with accuracy the 
future rate of menopause.The peri-menopausal years are a time period during which 
postmenopausal levels of FSH (greater than 20 IU/L) can be seen despite continued 
menstrual bleeding, while LH levels still remain in the normal range. Occasionally, corpus 
luteum formation and function occur, and the peri-menopausal woman is not safely beyond 
the risk of an unplanned and unexpected pregnancy until elevated levels of both FSH (>20 
IU/L) and LH (>30 IU/L) can be demonstrated. The median age for the onset of this 
transition was 47.5 years. Only 10% of women ceased men-struating abruptly with no 
period of prolonged irregularity. The peri-menopausal transition from reproductive to post-
reproductive status was, for most women, approximately 4 years in duration. In the study 
by Treloar, the average age for entry into the peri-menopausal transition was 45.1, and the 
age range that included 95% of the women was 39–51 (Treloar AE, 1996). The mean duration 
of the peri-menopausal transition was 5.0 years, with a range of 2 to 8 years.  
5.1 Endocrine activity of the peri and post-menopausal ovary 
As reviewed above, mean estradiol levels are normal or high in peri-menopausal women, 
and FSH levels are often not suppressed despite these high estradiol levels. These aspects of 
pituitary-ovarian relationships are contrary to expected physiology. It is proposed that, 
decreasing ovarian production of inhibin plays a role in the high average estrogen levels 
documented during the peri-menopause. More specifically, the B subtype of inhibin, a small 
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peptide made in ovarian granulosa cells, which is known to be stimulated by FSH and, in 
turn, to suppress FSH, may play a role in the altered physiology of the peri-
menopause (Klein NA, et al., 1996, 1998).  Increasing evidence suggests that ovarian 
inhibin plays a role in ovarian folliculogenesis (McLachlan RI, et al., 1986; Hughes EG,,et al., 
1992), therefore, new information about inhibin levels and their functional relationships 
in women in there forties and fifties becomes important.  
The peri and post-menopausal ovary contains two different populations of cells with 
steroidogenic capacity: hilar cells and cortico stromal cells that may represent residual thecal 
elements (De Roux N, et al., 1999).  In vitro studies suggest that the post-menopausal ovary 
has some steroidogenic potential. Incubation of post-menopausal ovarian stromal slices with 
pregnenolone yielded progesterone, dehydroepiandrosterone, and testosterone. Incubation 
of strips of ovarian hilar tissue from postmenopausal women revealed a steroidogenic 
pattern similar to that of the postmenopausal ovarian stroma. However, the overall amount 
of steroids produced was substantially greater compared with stroma. Measurable in vitro 
formation of estradiol by postmenopausal cortical stroma and hilar cells has also been 
reported (Bertherat J 1998: Ulloa-Aguirre A, et al., 1998).  
With increasing age, the adrenal contribution of precursors for estrogen production proves 
inadequate. In this final stage of estrogen availability, levels are insufficient to sustain 
secondary sex tissues. Estrogens in peri and post-menopausal women appear to arise almost 
exclusively from extra-glandular aromatization of androstenedione (Arora KK, et al., 1997). 
Oophorectomy results in no significant reduction in urinary estrogen excretion by post-
menopausal women. However, adrenalectomy after oophorectomy virtually eliminates 
measurable estrogens from the urine. In vitro studies concluded that the postmenopausal 
ovarian stroma is unable to aromatize androgens (Everest HM, et al., 2001).  However, 
others have suggested that the post-menopausal ovary may synthesize limited amounts of 
estrogens, because the concentrations of estradiol and estrone are two times higher in 
ovarian venous blood than in peripheral blood of post-menopausal women (Illing N, et al., 
1999).  
There is some evidence that ovarian androgen production in post-menopausal women can 
be gonadotropin dependent. Administration of hCG to postmenopausal women results in a 
small increase in the circulating levels of testosterone (Sun YM, et al).  Daily injection of hCG 
causes hyperplasia of the ovarian hilar cells and histochemical evidence suggestive of active 
steroidogenesis (Tensen C, et al., 1997). Administration of hCG, but not ACTH, resulted in 
increased androgen but not estrogen production by the ovaries (Wang L, et al., 2001). 
Binding sites for both LH and FSH were identified in the cortical stroma and in hilar cells 
(Davidson JS, et al., 1994). Addition of hCG to hilar cells results in increased cAMP 
formation and steroid biosynthesis, indicating preserved responsiveness to gonadotropins. 
Taken together, these observations suggest that ovarian androgen biosynthesis of the post-
reproductive ovary is at least partially gonadotropin dependent. 
The post-menopausal ovary is occasionally involved in pathologic endocrine activity. 
Stromal hyperplasia can occur, with the ovary enlarging with hyperplastic stromal nodules 
consisting of lipid-rich luteinized cells that resemble theca interna. The ovaries with stromal 
hyperplasia produce large amounts of androstenedione, resulting in hirsutism and 
virilisation (Vrecl M, et al., 1998).  Hilar cells can give rise to functional hilar cell tumors, 
which produce excess amounts of androgens, leading to virilisation (Pawson AJ, et al., 1998; 
Blomenrohr M, et al., 1999; Heding A, et al., 2000). Signs and symptoms of estrogen excess 
may also be evident in circumstances of significant peripheral aromatization.  
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6. Treatment of anovulation 
If no primary pathology is apparent, or if the primary pathology has been treated 
appropriately without restoration of normal endocrinology, treatment options lie between 
estrogen replacement (or the oral contraceptive in a younger woman) to prevent 
osteoporosis and ovulation induction to restore fertility. Estrogen antagonists usually are 
ineffective in inducing ovulation in progestogen-negative women, and treatment with 
pulsatile GnRH or gonadotropin treatment is normally required. (Elizur SE, et al., 2005).  
Treatment with pulsatile GnRH involves the woman carrying a small portable pump but 
has the important advantage of a lower multiple pregnancy rates than is seen with 
gonadotropin treatment. Women with a low LH concentration (<4 IU/L) require treatment 
with combined gonadotropin treatment regimens that include both FSH and LH bioactivity. 
The older urinary gonadotropin preparations have sufficient LH bioactivity, but when a 
recombinant FSH is used, it must be supplemented with recombinant LH or with a low 
dosage of urinary hCG.   
6.1 Ovulation inductions and assisted reproduction 
The reproductive period in women is characterized by their ability to ovulate. Ovulation, 
the release of an oocyte within the peritoneal cavity, follows rupture of a dominant follicle, 
developed in response to stimulation by endogenous gonadotropins. In the presence of 
normal fallopian tubes, the released oocyte will be able to interact with spermatozoa 
ascending the female genital tract. This may lead to production of the zygote and 
establishment of pregnancy if implantation occurs. When ovarian activity is disrupted, no 
ovulation takes place and, as a consequence, achievement of pregnancy is not feasible.  
Ovulation induction refers to exogenous direct or indirect stimulation of the ovary with the 
aim of alleviating sub-fertility due to anovulation. Ovulation induction should be 
differentiated from reestablishment of ovulation, which occurs after treatment of conditions 
interfering with the normal function of the hypothalamic-pituitary-ovarian (HPO) axis. 
These include weight and eating disorders, thyroid dysfunction, hyper-prolactinemia, and 
excess exercise. It should also be differentiated from enhancement of ovulation. This is usually 
performed in ovulatory women with unexplained infertility in the hope of increasing the 
probability of pregnancy. More important, ovulation induction must be differentiated from 
superovulation for in vitro fertilization (IVF), in which the aim of ovarian stimulation is to 
induce multi-follicular development. This   leads to the retrieval of multiple oocytes and 
thus allows the selection of the morphologically best embryo(s) for replacement. In IVF, 
follicular rupture is not necessary, because oocytes are collected by trans-vaginal aspiration 
(Pelinck MJ, et al., 2001; Castelo-Branco A, et al., 2004; Kolibianakis E, et al., 2002,2003). 
6.2 Ovarian stimulation regimens  
The ideal ovarian stimulation regimen for IVF should have a low cancellation rate, minimize 
drug costs, risks and side effects, require limited monitoring for practical convenience, and 
maximize singleton pregnancy rates. Numerous regimens have been described, ranging 
from no stimulation (natural cycles), to minimal stimulation (clomiphene citrate) or mild 
stimulation (sequential treatment with clomiphene citrate and low dose exogenous 
gonadotropins), to aggressive stimulation (high dose exogenous gonadotropins, alone or in 
combination with a gonadotropin-releasing hormone agonist or antagonist). Ovarian 
stimulation has been a basic element of IVF for more than 25 years, but concerns about 
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multiple pregnancies and the costs of IVF have sparked renewed interest in natural cycle 
IVF and mild stimulation regimens (Nargund G, et al., 2001) 
7. Natural cycle 
The first birth resulting from IVF derived from a single oocyte collected in a natural 
ovulatory cycle (Steptoe PC, & Edwards RG, 1978). Compared to stimulated IVF cycles, 
natural cycle IVF offers a number of attractive advantages. Natural cycle IVF involves only 
monitoring the spontaneous cycle and retrieving a single oocyte before the midcycle LH 
surge occurs. It is physically less demanding, requires little or no medication, decreases 
costs by 75–80%, (Aboulghar MA, et al., 1995; Nargund G, et al., 2001) and all but eliminates 
risks for multiple pregnancy and ovarian hyper-stimulation syndrome (OHSS). The chief 
disadvantages of natural cycle IVF are high cancellation rates due to premature LH surges 
and ovulation, and the comparatively low success rate, which is approximately 7% (Pelinck 
MJ, et al., 2002). When oocyte retrieval is based on detection of the mid-cycle rise in LH, 
careful and frequent monitoring is required and procedures are difficult to schedule 
efficiently.  
Alternatively, exogenous human chorionic gonadotropin (hCG) can be administered when 
the lead follicle reaches a size consistent with maturity, thereby better defining the optimum 
time for oocyte retrieval (Nargund G, et al., 2001). Adjuvant treatment with a GnRH 
antagonist also can be used to prevent a premature LH surge, but requires “add-back” 
treatment with exogenous FSH, and success rates are still quite low, ranging up to 14% per 
cycle in non-randomized trials (Castelo-Branco A, et al., 2004; Kolibianakis E, et al., 2002, 
2003; Weghofer A, et al., 2004; Elizur SE, et al., 2005). In one large cohort study involving 844 
treatment cycles in 350 good prognosis patients, the cancellation rate was 13%, the 
pregnancy rate was 8% per cycle and the cumulative pregnancy rate after three “modified 
natural IVF cycles” was 21% (Pelinck MJ, et al., 2002).  In a cohort of infertile couples with 
male factor infertility, success rates in modified natural cycles have reached as high as 13% 
per cycle, with a cumulative pregnancy rate of 44% after six treatment cycles (Verberg MF, 
et al., 2006). 
8. Clomiphene citrate 
Clomiphene citrate (CC) was the first method of ovarian stimulation used in IVF, (Quigley 
MM, et al., 1984) but now has been almost entirely replaced by more effective stimulation 
regimens using human menopausal gonadotropins (hMG) or FSH, in combination with a 
GnRH agonist or antagonist  (Macklon NS, et al., 2006).  Clomiphene (100 mg daily) usually 
is administered for 5–8 days, beginning on cycle day 3, and induces development of two or 
more follicles in most normally ovulating women, (Dickey RP, et al., 1998; Messinis IE & 
Milingos SD 1998; Ingerslev HJ, et al., 2001) although egg yields 1–3, are only slightly 
greater than in un-stimulated cycles and substantially lower than in cycles stimulated with 
exogenous gonadotropins (Ingerslev HJ, et al., 2001; Branigan EF & Estes MA 2000; 
MacDougall MJ, Tan SL, Hall V, et al., 1996).  
Cycle cancellation rates are somewhat lower than in natural cycles and the numbers of 
oocytes retrieved, embryos transferred, and pregnancy rates are greater. As in natural 
stimulates multi-follicular development more effectively than treatment with Clomiphene 
alone (Corfman RS, et al., 1993; Dor J, et al., 1992).  Drug costs and monitoring requirements 
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are moderately cycles, exogenous hCG is administered when the lead follicle reaches mature 
size and a GnRH antagonist can be used to prevent a premature endogenous LH surge. 
Sequential treatment with clomiphene (100 mg daily for 5 days) and modest doses of 
exogenous gonadotropins (150–225 IU daily beginning on the last day of clomiphene 
treatment or the day after) higher, but still substantially less than in standard stimulation 
regimens involving higher dose gonadotropin treatment after down-regulation with a long-
acting GnRH agonist (described below) (Weigert M, et al., 2002; Dhont M, et al., 1995). In 
one comparative trial, higher cancellation rates and lower pregnancy rates were observed in 
sequential clomiphene/gonadotropin cycles (Dhont M, et al., 1995).  In another, the 
sequential stimulation regimen yielded fewer oocytes and embryos, but pregnancy rates 
were similar and the risks of ovarian hyper-stimulation syndrome (OHSS) were lower 
(Weigert M, et al., 2002).  
In a randomized trial, sequential clomiphene/gonadotropin stimulation and GnRH 
antagonist treatment yielded a pregnancy rate comparable to that achieved with a more 
aggressive standard treatment protocol, (Lin YH, et al., 2006) confirming the results of two 
earlier retrospective studies, (Fiedler K & Ludwig M 2003; Williams SC, et al., 2002), but 
contrasting with those of another observing lower pregnancy rates (Mansour R, et al., 2003).  
9. GnRH agonist “flare” gonadotropins stimulation protocol 
The “short” or “flare” protocol is an alternative stimulation regimen designed to exploit 
both the brief initial agonistic phase of response to a GnRH agonist and the suppression that 
results from longer-term treatment (Padilla SL, et al., 1996; Garcia JE, et al., 1990).  In a 
typical standard short protocol, leuprolide acetate (1.0 mg daily) is administered on cycle 
days 2–4, continuing thereafter at a reduced dose (0.5 mg daily), and gonadotropin 
stimulation (225–450 IU daily) begins on cycle day 3. Later adjustments in the dose of 
gonadotropin stimulation, if needed, are based on response and indications for hCG 
administration are the same as in the long protocol (described above). An early meta-
analysis including seven clinical trials comparing the short and long GnRH agonist 
treatment regimens determined that the two protocols yielded similar cancellation and 
pregnancy rates: (Hughes EG, et al., 1992).  
A 2000 systematic review including 22 trials concluded that pregnancy rates achieved with 
the long protocol were superior to those using the flare regimen (OR=1.27, CI=1.04–1.56) 
overall, (Daya S., 2000), but the analysis did not control for diagnosis and other prognostic 
factors and results may not apply to all women, or to poor responders in particular. 
Whereas some have observed improved follicular response and lower cycle cancellation 
rates in poor responders treated with a flare protocol, pregnancy and live birth rates 
remained low (Karande V, et al., 1997; Karacan M, et al., 2001). Decreased scheduling flare 
exibility is a distinct disadvantage of the flare is protocol, unless the onset of menses is 
controlled by preliminary treatment with an OC. The regimen also can result in a significant 
increase in serum progesterone and androgen levels, presumably resulting from late corpus 
luteum rescue, (San Roman GA, et al., 1992) which may adversely affect oocyte quality and 
fertilization and pregnancy rates (Loumaye E, et al., 1989). The “OC micro-dose GnRH 
agonist flare” stimulation regimen is a variation of the standard short protocol involving 14–
21 days of preliminary ovarian suppression with an OC (one pill daily), followed by micro-
dose leuprolide treatment (40 μg twice daily) beginning 3 days after discontinuation of OC 
treatment, and high-dose gonadotropin stimulation (300–450 IU daily) starting on day 3 of 
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leuprolide therapy. Indications for later gonadotropin dose adjustments and hCG 
administration are the same as in other stimulation regimens. Its primary advantage over 
the standard short protocol is that it does not induce any increases in serum progesterone or 
androgen concentrations, possibly because the doses of GnRH agonist administered are 
much lower, but likely also because preliminary OC treatment all but eliminates the 
possibility there may be a corpus luteum left to respond (Gonen Y, et al., 1990; Cedrin-
Durnerin et al., 1996). The OC-micro-dose GnRH agonist flare protocol may be useful in 
previous poor responders, in whom it can stimulate increased endogenous FSH release and 
may yield lower cancellation rates and higher peak serum estradiol levels, transfer rates and 
pregnancy rates (Surrey ES, et al., 1998; Scott RT et al., 1994) GnRH Antagonist 
Gonadotropin Stimulation Protocol. 
The introduction of GnRH antagonists into clinical practice provided another option for 
ovarian stimulation in ART. In contrast to the long-acting agonists, which first stimulate and 
later inhibit pituitary gonadotropin secretion by desensitizing gonadotropes to GnRH via 
receptor down-regulation, the antagonists block the GnRH receptor in a dose-dependent 
competitive fashion and have no similar flare effect (Matikainen T, et al., 1992; Reissmann T, 
et al., 1974,1995) gonadotropin suppression is almost immediate. GnRH antagonists offer 
several potential advantages over agonists. First, the duration of treatment for an antagonist 
is substantially shorter than for an agonist. Since its only purpose is to prevent a premature 
endogenous LH surge and its effects are immediate, antagonist treatment can be postponed 
until later in follicular development (after 5–6 days of gonadotropin stimulation), after 
estradiol levels are already elevated, thereby eliminating the estrogen deficiency symptoms 
that may emerge in women treated with an agonist (Olivennes F, et al., 2002).   
Second, because any suppressive effects that agonists may exert on the ovarian response to 
gonadotropin stimulation also are eliminated, the total dose and duration of gonadotropin 
stimulation required is decreased (Olivennes F, et al., 2002; Albano C, et al., 2000). For the 
same reason, GnRH antagonist stimulation protocols may benefit women who are poor 
responders when treated with a standard long protocol  (Olivennes F, et al., 2003; Akman 
MA, et al., 2001). Third, by eliminating the flare effect of agonists; GnRH antagonists avoid 
the risk of stimulating development of a follicular cyst.  Finally, the risk of severe OHSS 
associated with use of antagonists also appears lower than with agonists. GnRH antagonists 
have some potential disadvantages. When administered in small daily doses, strict 
compliance with the prescribed treatment regimen is essential (Olivennes F, et al., 2002).  
Antagonists suppress endogenous gonadotropin secretion more completely than agonists. 
Whereas the low levels of LH observed during agonist treatment are usually sufficient to 
support normal follicular steroid-genesis during stimulation with uFSH or rFSH, the even 
lower concentrations in women treated with an antagonist may not be. Indeed, serum 
estradiol levels may plateau or fall when antagonist treatment begins (Olivennes F, et al 
2002;, de Jong D, et al., 2001).   Although follicular growth appears unaffected, most prefer to 
add or substitute a low dose of hMG (75 IU) at the same time if it was not already part of the 
stimulation regimen. Evidence also suggests that pregnancy rates in antagonist treatment 
cycles may be modestly lower than in cycles using agonists in the long protocol (Al-Inany et 
al., 2006).  
The two GnRH antagonists available for clinical use, ganirelix and cetrorelix, are equally 
potent and effective. For both, the minimum effective dose to prevent a premature LH surge 
is 0.25 mg daily, administered sub-cutaneously (Albano C, et al., 1997).  Either can be 
administered in a series of small daily doses (0.25 mg). The treatment protocol may be fixed 
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and begin after 5–6 days of gonadotropin stimulation, (Albano C, et al., 1997; Diedrich K, et 
al., 1994), or tailored to the response of the individual, starting treatment when the lead 
follicle reaches approximately 13–14 mm in diameter. The individualized treatment regimen 
generally requires fewer total doses and may yield better overall results (Ludwig M, et al., 
2002). Alternatively, a single larger dose of cetrorelix (3.0 mg) will effectively prevent an LH 
surge for 96 hours. If given on day 6–7 of stimulation, the interval of effective suppression 
will encompass the day of hCG administration in most women (75–90%); the remainder may 
receive additional daily doses (0.25 mg) as needed, ending on the day of hCG treatment 
(Olivennes F, et al 1995; Olivennes F, et al., 2000; Olivennes F, et al., 2003). The single dose 
antagonist treatment regimen also can be withheld until the lead follicle reaches 13–14 mm 
in diameter (Fanchin R, et al., 2003,2005).  
A common variation of the antagonist stimulation regimen uses preliminary treatment with 
an OC to control the onset of menses, typically ending approximately 5 days before the 
scheduled start, which also may help to synchronize the follicular cohort before stimulation 
begins. Another variation advocated for poor responders uses micronized estradiol (2 mg 
twice daily, administered orally, beginning on day 21 of the preceding cycle) to suppress 
FSH during the late luteal phase for the same purpose, ending on the day before 
gonadotropins stimulation begins, (Fanchin R, et al 2003, 2005), or continuing through the 
first 3 days of gonadotropin stimulation (Hill MJ, et al., 2009).  The improved follicular 
dynamics observed are similar to those achieved by down-regulation with a GnRH agonist 
in the long protocol. The rebound increase in endogenous FSH levels that follows the 
discontinuation of estradiol treatment also may synergize with exogenous gonadotropins to 
promote multi-follicular development (de Ziegler D, et al., 1998; Fanchin R, et al., 2003).  
Results of a number of early trials comparing a fixed antagonist treatment protocol to the 
standard long protocol suggested that the two stimulation regimens yielded similar 
pregnancy rates (Albano C, et al., 2000; Olivennes F, et al., 2000); The European Middle East 
Orgalutran Study Group, 2001; Fluker M, et al., 2001).  However, a 2006 systematic review 
and meta-analysis including 27 trials comparing different antagonist stimulation protocols 
with the long GnRH agonist protocol observed a significantly lower clinical pregnancy rate 
(OR=0.84, CI=0.72–0.97) and ongoing pregnancy/live birth rate (OR=0.82, CI=0.69–0.98). 
Overall, the total dose and duration of gonadotropin stimulation required, peak serum 
estradiol levels, and the number of follicles and oocytes were lower in antagonist cycles. 
 The explanation for the modestly lower pregnancy rates observed in antagonist treatment 
cycles is not clear. It is possible, but unlikely, that GnRH antagonists may have adverse 
effects on oocytes, embryos, or the endometrium (Hernandez ER 200; Ortmann O, et al., 
2001). It is far more likely that early results reflected inexperience and improved with time 
and further refinements in the treatment regimen like those described above. Many of the 
advantages originally envisioned for GnRH antagonists already have been realized. 
Whether antagonists ultimately will replace agonists and become the standard ovarian 
stimulation regimen in ART cycles remains to be seen, but their place in the therapeutic 
arsenal already is firmly established.  Whereas a single bolus injection of an agonist 
(leuprolide 0.5 mg, triptorelin 0.2 mg) triggers a physiologic LH surge that lasts less than 24 
hours, hCG levels remain elevated for several days and stimulate markedly higher estradiol 
and progesterone concentrations (Fauser BC, et al., 2002).  
The antagonist treatment regimens currently in use have potential disadvantages for women 
with PCOS. Their tonically elevated LH levels will remain high until antagonist treatment 
begins. Consequently, LH levels may rise prematurely, particularly if antagonist treatment 
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is withheld until the lead follicle reaches 14 mm or more. Moreover, evidence indicates that 
increased LH exposure during early follicular development may be detrimental and 
predispose to lower pregnancy rates (Kolibianakis E, et al., 2002; Kolibianakis EM, et al., 
2003; Kolibianakis EM, et al., 2003; Kolibianakis E, et al., 2003).  In theory, pre-treatment with 
an OC might prove quite useful by suppressing LH and androgen levels before stimulation 
begins, decreasing exposure during early follicular development and the risk of rising LH 
levels before antagonist treatment starts. Preliminary OC suppression and later antagonist 
treatment may help to limit the follicular response to gonadotropin stimulation while 
preserving the option to use an agonist to trigger final oocyte maturation. These 
considerations simply serve to illustrate that GnRH antagonists are not a panacea and are 
not necessarily the best choice even for women with PCOS. Antagonist stimulation 
protocols are advocated for poor responders, primarily because they avoid the suppressive 
effects that agonists can have on follicular response and can prevent the premature LH 
surges observed commonly in women stimulated with gonadotropins alone (Surrey ES & 
Schoolcraft WB., 2000).  However, evidence is insufficient to indicate they yield results 
consistently better than other stimulation regimens (Pandian Z, et al., 2010; Centers for 
Disease Control and Prevention, Atlanta, GA, 2009). 
10. Ovarian reserve 
The concept of ovarian reserve, generally defined as the size and quality of the remaining 
ovarian follicular pool, and the various methods for its measurement. The total number of 
oocytes in any given women is genetically determined and inexorably declines throughout 
life, from approximately 1–2 million at birth, to about 300,000 at puberty, 25,000 at age 40, 
and fewer than 1,000 at menopause (Battaglia DE, et al., 1996; Faddy MJ & Gosden RG, 
1996).  The rate of follicular depletion is not constant, but increases gradually as the number 
of follicles remaining decreases (Nilsson E, et al., 2007; Adhikari D & Liu K, 2009; Da Silva-
Buttkus P, et al., 2009; Coxworth JE, & Hawkes K, 2010).  As the size of the remaining 
follicular pool decreases, circulating inhibin-B levels (derived primarily from smaller antral 
follicles) decrease, resulting in lower levels of feedback inhibition and a progressive increase 
in serum follicle-stimulating hormone (FSH) levels, most noticeably during the early 
follicular phase (Klein NA, et al., 1996; Welt CK, McNicholl DJ, Taylor AE, et al; Hale GE, et 
al., 2007 ; Knauff EA, et al., 2009; Burger HG,  et al., 2008).  Increasing inter-cycle FSH 
concentrations stimulate earlier follicular recruitment, resulting in advanced follicular 
development early in the cycle, an earlier rise in serum estradiol levels, a shorter follicular 
phase, and decreasing overall cycle length (Klein NA, et al., 2002; de Koning CH, et al., 
2008).  
The physiology of reproductive aging provides the foundation for all contemporary tests of 
ovarian reserve. In clinical practice, the basal early follicular phase (cycle day 2–4) FSH level 
is the most common test, but antimüllerian hormone (AMH) and antral follicle count are 
alternatives having significant potential advantages. As basal FSH levels increase, peak 
estradiol levels during stimulation, the number of oocytes retrieved, and the probability for 
pregnancy or live birth decline steadily (Pearlstone AC, et al., 1992; Scott Jr RT & Hofmann 
GE, 1995; Bukman A, & Heineman MJ, 2001). With current assays (using IRP 78/549), FSH 
levels greater than 10 IU/L (10–20 IU/L) have high specificity (80–100%) for predicting poor 
response to stimulation, but their sensitivity for identifying such women is generally low 
(10–30%) and decreases with the threshold value  (Broekmans FJ, et al., 2006) .  Although 
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most women who are tested have a normal result, including those with a diminished 
ovarian reserve (DOR), the test is still useful because those with abnormal results are very 
likely to have DOR. In a 2008 study, an FSH concentration above 18 IU/L had 100% 
specificity for failure to achieve a live birth (Scott Jr RT, et al., 2008).  The basal serum 
estradiol concentration, by itself, has little value as an ovarian reserve test (Hazout A, et al., 
2004; Eldar-Geva T, et al., 2005; McIlveen M, et al., 2007), but can provide additional 
information that helps in the interpretation of the basal FSH level. An early elevation in 
serum estradiol reflects advanced follicular development and early selection of a dominant 
follicle (as classically observed in women with advanced reproductive aging), and will 
suppress FSH concentrations, thereby possibly masking an otherwise obviously high FSH 
level indicating DOR. When the basal FSH is normal and the estradiol concentration is 
elevated (>60–80 pg/mL), the likelihood of poor response to stimulation is increased and 
the chance for pregnancy is decreased (Evers JL, et al., 1998; Buyalos RP, al., 1997). When 
both FSH and estradiol are elevated, ovarian response to stimulation is likely to be very 
poor. Antimüllerian hormone (AMH) derives from pre-antral and small antral follicles. 
Levels are gonadotropin-independent and vary little within and between cycles  (Fanchin R, 
et al., 2005; Tsepelidis S, et al., 2007; Hehenkamp WJ, et al., 2006).  The number of small 
antral follicles correlates with the size of the residual follicular pool and AMH levels decline 
progressively with age, becoming undetectable near the menopause (Sowers MR, et al., 
2008; van Rooij IA, et al., 2004; van Rooij IA, et al., 2005).  
10.1 Oocyte and ovarian tissue cryopreservation 
Each year, cancer occurs in approximately 100 per 100,000 women under age 50 in the 
United States. Chemotherapy and radiation therapy for malignant and non-malignant 
systemic disease very often results in ovarian failure. Women with cancer and other serious 
illnesses requiring treatments that pose a serious threat to their future fertility have 
relatively few options. In some cases, the ovaries may be moved out of the radiation field. 
Treatment with GnRH agonists has been suggested as a way to protect the gonads from the 
insult of chemotherapy, but there is no convincing evidence for its efficacy. Although 
embryo banking is effective, the time required for stimulation and retrieval are often 
prohibitive. With recent advances in cryobiology, oocyte and ovarian tissue 
cryopreservation hold promise as methods to preserve reproductive potential (Shaw JM, et 
al., 2000).  
10.2 Oocyte cryopreservation 
Although the first pregnancy resulting from oocyte cryopreservation was reported in 1986, 
(Chen C, 1986), success rates achieved with the technology were historically very low, and 
only recently improving. The primary obstacle was the poor survival of oocytes, which are 
fragile due to their size, high water content, and chromosomal arrangement; the meiotic 
spindle is easily damaged by intracellular ice formation during freezing or thawing (Shaw 
JM, et al., 2000). Germinal vesicle stage oocytes are hardier, (Boiso I, et al., 2002), but 
progress with in vitro maturation of immature oocytes has been slow. Another obstacle was 
hardening of the zona pellucida, which interfered with normal fertilization. The improved 
survival of cryopreserved oocytes today relates primarily to modifications in the sucrose 
and sodium concentrations in traditional “slow-freeze” protocols, (Fabbri R, et al., 2001; 
Stachecki JJ & Willadsen SM, 2000; Bianchi V, et al., 2007; De Santis L, et al., 2007), changes.,  
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in the initial temperature of the cryoprotectant, and-seeding temperature (Trad FS, et al., 
1999). Survival rates have been further improved with vitrification, a technique that uses 
high concentrations of cryoprotectant and rapid freezing by immersion in liquid nitrogen, 
preserving oocytes in a solid glass-like state without ice formation (Loutradi KE, et al., 2008; 
Oktay K, et al., 1997). With the use of intra-cytoplasmic sperm injection (ICSI), the hardened 
zona is not a barrier to fertilization (Polak de Fried E, et al., 1998).  Survival, fertilization, and 
pregnancy rates achieved with cryopreserved oocytes are rap-idly improving and 
approaching those achieved with fresh oocytes (Grifo JA, & Noyes N, 2010; Nagy ZP, et al., 
2009). A randomized comparison of results achieved with slow-freeze and vitrification 
observed that vitrification resulted in better oocyte survival (81% vs. 67%), fertilization (77% 
vs. 67%), and clinical pregnancy rates per thawed oocyte (5.2% vs. 1.7%).  
A study examining outcomes achieved with vitrified donor oocytes observed 87% thaw 
survival, 87% fertilization, and 68% blastocyst formation, with 15/20 recipients (75%) 
achieving pregnancy after embryo transfer (Cobo A, Kuwayama M, Perez S, et al).  Another 
using both slow-frozen and vitrified oocytes observed 92% survival, 79% fertilization, 42% 
implantation, and a 57% on going pregnancy rate (Grifo JA & Noyes N, 2010). Although the 
number of pregnancies and deliveries resulting from oocyte cryopreservation is still 
somewhat small, the number is rapidly increasing, and early perinatal outcomes data are 
reassuring. The incidence of chromosomal abnormalities in human embryos derived from 
cryopreserved oocytes is no different from that observed in control embryos derived from 
fresh oocytes (Gook DA, et al., 1994; Cobo A, et al., 2001).  A study comparing outcomes in 
200 infants derived from vitrified oocytes and in infants resulting from conventional fresh 
IVF found no differences in birth weight or in the incidence of birth defects (Chian RC, et al., 
2008).  A review of over 900 live births resulting from IVF of cryopreserved oocytes also 
observed no increase in the prevalence of congenital anomalies compared to that in the 
general population (Noyes N, et al., 2009). Oocyte cryopreservation is a viable fertility 
preservation strategy for women without partners seeking to preserve their fertility. 
Unfortunately few cancer patients have sufficient time to undergo ovarian stimulation 
before their treatment begins. The technology also holds enormous promise as a means to 
simplify oocyte donation, via egg banking, and is rapidly emerging as an elective fertility 
preservation strategy for women anticipating delayed childbearing and concerned about 
their future fertility. Currently, elective oocyte cryopreservation to defer reproductive aging 
is controversial, primarily because the great majority of outcomes data have come from 
experience with cryopreserved oocytes obtained from healthy young oocyte donors and 
cannot be extrapolated to older women who represent the majority of those expressing 
interest in elective oocyte cryopreservation (Rybak EA & Lieman HJ 2009; ASRM Practice 
Committee). However, when age-stratified outcomes data become available, allowing 
women to be accurately informed about their prognosis for success, elective oocyte 
cryopreservation may realistically offer women the means to set their “biological clock.” 
10.2.1 Ovarian tissue cryopreservation  
At least in theory, ovarian tissue cryopreservation offers the means to freeze thousands of 
primordial follicles for later in vitro maturation or to store tissue for xenografting into an 
animal host or later auto transplantation (Jeruss JS, Woodruff TK., 2009).  Currently, 
autologous transplantation of ovarian tissue seems the most practical and effective approach 
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because the technique has successfully restored fertility to women with ovarian failure 
resulting from cancer chemotherapy (Andersen CY,, et al., 2008; Demeestere I, 2006,2010; et 
al; Silber SJ 2009).  Ovarian tissue is removed surgically via laparoscopy or laparotomy and 
frozen using either a slow-cool or vitrification technique, before the insult expected to result 
in ovarian failure. Later, it can be thawed and transplanted back into the patient in or near 
its original location (orthotopic transplantation) or to another site, such as the forearm or 
abdominal wall (heterotopic transplantation). The advantage of orthotopic transplantation is 
that pregnancy might be achieved without assistance, whereas heterotopic transplantation 
requires IVF (Jeruss JS & Woodruff TK. 2009). Live births have been achieved after 
transplantation of frozen-thawed ovarian tissue in sheep, (Candy CJ et al., 2000) and the first 
live birth in a primate after a fresh heterotopic ovarian transplantation has been reported 
(Lee DM, et al).  Human oocytes have been obtained from heterotopic transplants and 
fertilized in vitro to yield embryos for transfer, resulting in a biochemical pregnancy 
(Rosendahl M, et al., 2006). The only human pregnancy achieved after heterotopic 
transplantation was achieved without assistance, indicating that the oocyte from which it 
arose came from the patient’s existing ovary rather than from the transplant.  Orthotopic 
transplantation has been successfully achieved in humans.  
A number of live births have been reported after autologous orthotopic transplantation of 
cryopreserved ovarian tissue. Frozen ovarian tissue also has been transplanted successfully 
between monozygotic twin sisters after the receiving twin developed premature ovarian 
failure (Silber SJ, & Gosden RG, 2007). A 2008 systematic review identified 25 reports 
describing a total of 46 cases of ovarian tissue transplantation for treatment of premature 
ovarian failure or infertility, although most involved transplantation of fresh rather than 
frozen ovarian tissue (Bedaiwy MA, et al., 2008).  The mean time to return of ovarian 
function was 120 days (range 60–244 days) and data were insufficient to evaluate function 
beyond 1 year. Fresh grafts were more likely to succeed, and in 25 women who sought 
pregnancy, eight conceived nine pregnancies. At least one potential risk of ovarian tissue 
cryopreservation and auto-transplantation is reseeding of tumor cells in women with 
malignancies. Future research focusing on defining patient suitability, tissue collection 
methods, and cryopreservation protocols is certainly warranted, but until effective 
techniques and the possibility for success can be defined, ovarian tissue cryopreservation 
will remain investigational and cannot be justified solely for the purpose of future use in 
healthy women. 
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